Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is projected to experience strong revenue growth through the expansion of its prenatal and oncology segments, as well as the launch of a pan-cancer MRD test in 2026. The company has a strong roadmap for future growth and has achieved profitability, fueled by its proprietary QCT molecular counting platform. However, competition is a factor to consider, and the company plans to invest in growth initiatives to maintain its competitive edge in the rapidly expanding market for cancer testing. With a seasoned CFO and successful fundraising efforts by the CEO, BillionToOne is positioned for success in the long-term.

Bears say

BillionToOne is a molecular diagnostics company that offers a portfolio of ultrasensitive tests for prenatal genetic testing and cancer therapy selection and monitoring. However, despite the potential and early success of its products, there are concerns about slow adoption rates and potential competition in the market. Additionally, reimbursement and pricing could be a risk for BillionToOne. This, coupled with slower than expected revenue growth, could explain the negative outlook on the company's stock.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.